



(51) International Patent Classification:

C07D 471/06 (2006.01) A61K 31/4375 (2006.01)
C07D 471/16 (2006.01) A61K 31/4985 (2006.01)
C07D 487/06 (2006.01) A61K 31/536 (2006.01)
C07D 519/00 (2006.01) A61P 31/04 (2006.01)
A61K 31/437 (2006.01)

(21) International Application Number:

PCT/IB2009/054357

(22) International Filing Date:

6 October 2009 (06.10.2009)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

PCT/IB2008/054109

7 October 2008 (07.10.2008)

IB

PCT/IB2009/051059 13 March 2009 (13.03.2009)

IB

PCT/IB2009/052843 30 June 2009 (30.06.2009)

IB

(71) Applicant (for all designated States except US): **ACTELION PHARMACEUTICALS LTD** [CH/CH];
Gewerbstrasse 16, CH-4123 Allschwil (CH).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **HUBSCHW-ERLEN, Christian** [FR/CH]; c/o Actelion Pharmaceuticals Ltd, Gewerbstrasse 16, CH-4123 Allschwil (CH).

RITZ, Daniel [CH/CH]; c/o Actelion Pharmaceuticals Ltd, Gewerbstrasse 16, CH-4123 Allschwil (CH).
RUEEDI, Georg [CH/CH]; c/o Actelion Pharmaceuticals Ltd, Gewerbstrasse 16, CH-4123 Allschwil (CH).
SURIVET, Jean-Philippe [FR/CH]; c/o Actelion Pharmaceuticals Ltd, Gewerbstrasse 16, CH-4123 Allschwil (CH).
ZUMBRUNN ACKLIN, Cornelia [CH/CH]; c/o Actelion Pharmaceuticals Ltd, Gewerbstrasse 16, CH-4123 Allschwil (CH).


(74) Agent: **RUHLMANN, Eric**; c/o Actelion Pharmaceuticals Ltd, Legal Department, Gewerbstrasse 16, CH-4123 Allschwil (CH).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,

[Continued on next page]

(54) Title: TRICYCLIC OXAZOLIDINONE ANTIBIOTIC COMPOUNDS



(57) Abstract: The invention relates to antibacterial compounds of formula (I) wherein $\square$ --- $\square$ is a bond or is absent, V is CH, CR⁶ or N; R⁰ is H or, if $\square$ --- $\square$ is a bond, may also be alkoxy; R¹ is notably H or halogen; U is CH or N when $\square$ --- $\square$ is a bond, or, if $\square$ --- $\square$ is absent, U is CH₂, NH or NR⁹; R² is H, alkylcarbonyl or [CH₂-R³]; R³ is H, alkyl or hydroxyalkyl; R⁴ is H or, if n is not 0 and R⁵ is H, may also be OH; R⁵ is H, alkyl, hydroxyalkyl, aminoalkyl, alkoxyalkyl, carboxy or alkoxy-carbonyl; R⁶ is hydroxyalkyl, carboxy, alkoxy-carbonyl or -(CH₂)_q-NR⁷R⁸, q being 1, 2 or 3 and each of R⁷ and R⁸ independently being H or alkyl or R⁷ and R⁸ forming with the N atom bearing them a ring; R⁹ is alkyl or hydroxyalkyl; A is -(CH₂)_p-, -CH₂CH₂CH(OH)- or -COCH₂CH(OH)-; G is substituted phenyl or G¹ or G², wherein Q is O or S and X is CH or N; and Y¹, Y² and Y³ may each be CH or N; and n is 0 when A is -CH₂CH₂CH(OH)- or -COCH₂CH(OH)-, and n is 0, 1 or 2 when A is -(CH₂)_p-, p being 1, 2, 3 or 4, with the proviso that the sum of n and p is then 2, 3 or 4; and to salts of such compounds.



ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, **Published:**

TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
ML, MR, NE, SN, TD, TG).

— *with international search report (Art. 21(3))*